Printer Friendly

CURATIVE TECHNOLOGIES REPORTS ON PROGRESS AT ANNUAL SHAREHOLDERS MEETING

 EAST SETAUKET, N.Y., May 25 /PRNewswire/ -- At its annual meeting of shareholders today, Curative Technologies, Inc. (Nasdaq-NNM: CURE) reported on 1993 performance and planned efforts to achieve continued growth during 1994.
 During 1993, the Wound Care Business Unit added 11 new Wound Care Centers(R) and three subacute care centers, ending the year with 56 operating programs. To date in 1994, the company has opened or has contracted to open a total of 58 Wound Care Centers and four subacute care programs, bringing the number of total programs to 62.
 "New business development appears strong at this time and we are optimistic that the Wound Care Business Unit will continue its history of strong revenue growth," said Russell B. Whitman, President and Chief Executive Officer.
 At the annual meeting, Mr. Whitman highlighted CTI's technological strengths. The company is continuing to progress in the enrollment of patients for pivotal clinical trials using CT102. On the basis of encouraging preclinical findings with CT112, a proprietary therapeutic new drug candidate, the company is pursuing a strategic partner for its line of small peptides. The initial applications will be in the area of immune modulation and control of inflammation with the primary focus on rheumatoid arthritis.
 In addition, Mr. Whitman announced that the Board of Directors has established an Executive Committee that will report to the Board on specific initiatives the company can pursue which would tighten the focus of its business mission and ensure resources are deployed in such a way as to maximize shareholder value.
 Curative Technologies, Inc. is a technology driven healthcare company that has established itself as a leader in wound healing by providing a range of specialty products and services to healthcare providers through a nationwide network of Wound Care Centers(R). The company is also engaged in the research, development, production and marketing of therapeutic products utilizing naturally occurring human growth factors.
 -0- 5/25/94
 /CONTACT: Russell B. Whitman of Curative Technologies, 516-689-7000; or Kathryn Comba, 212-696-4455, ext. 206, or Rhonda Chiger, 212-696-4455, ext. 207, both of Noonan/Russo Communications/
 (CURE)


CO: Curative Technologies, Inc. ST: New York IN: HEA SU:

CB-OS -- NY035 -- 0168 05/25/94 10:08 EDT
COPYRIGHT 1994 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1994 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 25, 1994
Words:364
Previous Article:1995 BUSINESS PROCESS AND WORKFLOW CONFERENCE ANNOUNCED
Next Article:PACIFIC GAS AND ELECTRIC SELECTS STONE & WEBSTER FOR CLEAN AIR WORK
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters